Genelux Corporation · NASDAQ:GNLX
Genelux — Investor Presentation (August 2026)
46 slides from Genelux's investor presentation, August 2026
Slide 1: Redefining Immuno-Oncology
Redefining Immuno-Oncology Corporate Presentation August 2026
Slide 2: Disclaimer
Disclaimer This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are subject to the “safe harbor” created by those sections, about Genelux Corporatio
Slide 3: Highlights
Highlights Olvi-Vec: late-stage Clinical Program focused on Platinum Sensitization in Multiple Indications Ongoing pivotal Phase 3 trial in late-stage platinum resistant/refractory ovarian cancer (PRROC) Alignment reached with FDA that could potentially support a traditional approval without need fo
Slide 4: A Maturing Modality with Phase 3 Companies Validating Oncolytic Virus Potential
A Maturing Modality with Phase 3 Companies Validating Oncolytic Virus Potential Systemic Next Generation Delivery Potential to be Regional & Systemic First-in-Class Administration Across multiple tumor types Phase 2 Ovarian Cancer Apparent tumor re-sensitization to platinum-based therapy Limitations
Slide 5: The Most Advanced Non-local Delivery Oncolytic Immunotherapy
The Most Advanced Non-local Delivery Oncolytic Immunotherapy Olvi-Vec: 7 Completed Clinical Trials (>150 Patients) Physician-preferred Antitumor Effect Ideal Backbone of routes of delivery and Well Tolerated Combination Therapy ▪ Regional and Systemic Administration to ▪ Strong ORR, mPFS & mOS data
Slide 6: Program Builds on Completed Trials to Exploit Competitive Advantages
Program Builds on Completed Trials to Exploit Competitive Advantages ➢ Therapy (platinum sensitization in multiple indications) Upcoming Trial Readouts have Potential to Redefine: ➢ Modality (systemic administration of an oncolytic virus) Anticipated Olvi-Vec Indication Design Preclinical Phase 1 Ph
Slide 7: 2026 Financial Guidance Reflects Advancing the Olvi-Vec Pipeline
2026 Financial Guidance Reflects Advancing the Olvi-Vec Pipeline Cash: Quarterly CapEx: Cash Runway: Operating Cash Burn (avg.): ~$19M Up to ~$6M Q1’27 ~$7M Expectations for 2026: o Topline readout of registrational trial in ovarian cancer o Additional systemic dose-finding updates in lung cancer o
Slide 8: Regional Administration Program
Regional Administration Program Ovarian Cancer 8
Slide 9: Ovarian Cancer Program: Regional (Intraperitoneal) Delivery
Ovarian Cancer Program: Regional (Intraperitoneal) Delivery Completed and ongoing clinical trials in heavily pre-treated platinum resistant/refractory patients Key Takeaways Trial Sites Clinical Design Patients Randomization Status Location / (#) Stage • Phase 1 tested condensed dosing Combination s
Slide 10: Phase 3 Pivotal Trial Design Founded on Phase 2 Trial Design & Results
Phase 3 Pivotal Trial Design Founded on Phase 2 Trial Design & Results Trial design intends to replicate previous data showing anti-tumor activity of Olvi-Vec and reversal of platinum resistance/refractoriness. Key Inclusion Criteria Multi-center, randomized open-label1 Primary Endpoint n=186 • High
Slide 11: Completed Phase 1b Anti-tumor Activity as Monotherapy Leading into Combination
Completed Phase 1b Anti-tumor Activity as Monotherapy Leading into Combination Olvi-Vec Monotherapy1 Patient Background & Study Treatment Key Clinical Takeaways • Heavily pre-treated PRROC patients with documented progressive disease • Cohort 1 received a single cycle of intraperitoneal delivery on
Slide 12: Completed Phase 2 Tested Olvi-Vec-primed Immunochemotherapy
Completed Phase 2 Tested Olvi-Vec-primed Immunochemotherapy Heavily Pretreated Patients with Platinum-Resistant or Platinum-Refractory Ovarian Cancer Data Presentations Key Inclusion Criteria Interventional Single Group Assignment 1. 2020 Digital Annual Meeting of International n=27 Gynecologic Canc
Slide 13: Phase 2: Clinically-Meaningful Responses in Heavily Pretreated Patients
Phase 2: Clinically-Meaningful Responses in Heavily Pretreated Patients Overall Response Rate (ORR), including Complete Responses (CR) & Partial Responses (PR), and Progression-Free Survival (PFS)* Key Clinical Takeaways Median ORR by Duration of ORR by Median Overall RECIST1.1** Response CA-125 PFS
Slide 14: Demonstrated Deep and Durable Tumor Shrinkage
Demonstrated Deep and Durable Tumor Shrinkage Tumor Shrinkage 100 133 24 58 81 62 132 19 46 45 53 129 31 253 70 124 48 145 65 138 83 82 12 Change of target lesion size (% Key Clinical Takeaways 80 Baseline tumor burden as Sum of Longest Diameter of target lesions (mm) 60 change of SLD) 40 Refractory
Slide 15: Olvi-Vec-Primed Immunochemotherapy Overcomes “Refractoriness”
Olvi-Vec-Primed Immunochemotherapy Overcomes “Refractoriness” Exemplary platinum-refractory patients, after platinum re-challenge, achieved PFS exceeding any prior lines 15B-01: 15B-15: 15B-17: • Stage IIIB papillary • Stage IIIB high- • Stage IIIC high- serous grade serous grade serous • ECOG: 0 •
Slide 16: Meaningful clinical benefit: Relative to patients’ preceding line of therapy
Meaningful clinical benefit: Relative to patients’ preceding line of therapy Key Clinical Takeaways ‘PFS ratio’ in the same patients = (PFS+1 post-Olvi-Vec) / (PFS-1 pre-Olvi-Vec) Promising PFS and clinical reversal of platinum resistance and refractoriness among patients with PRROC • All patients h
Slide 17: Durable Survival Benefit
Durable Survival Benefit Prognosis Worsens with each Successive Line [mOS in months] Historical Data1 ELAHERE2 2nd line 21.1 mOS (95% CI, 17.8-24.4) 18.7 mOS (2nd/3rd) 3rd line 12.9 mOS (95% CI, 10.4-14.6) Key Clinical Takeaways 4th line 9.8 mOS (95% CI, 7.1-12.25) 11.6 mOS 1.0 5th line Not reported
Slide 18: Phase 2 Compared to Approved Standard of Care in Earlier Lines
Phase 2 Compared to Approved Standard of Care in Earlier Lines Elahere Enhertu Lifyorli+Nab-paclitaxel Olvi-Vec Phase 3 Phase 2 Phase 3 Phase 2 (MIRASOL Study) (DESTINY-PanTumor02) (ROSELLA Study) (VIRO-15 Study) FRα positive and platinum-resistant Platinum –resistant HER2 positive IHC3+, or IHC2+ P
Slide 19: Self Launch of Olvi-Vec for Ovarian Cancer in the US
Self Launch of Olvi-Vec for Ovarian Cancer in the US Drivers of Market Penetration Growing Market Concentrated Reimbursement Self-Manufacturing Opportunity Prescribing Network Authorities No Entrenched Competitor in Manageable Commercial Large-Scale Proprietary Compelling Value Proposition 4th Line
Slide 20: Systemic Administration Programs
Systemic Administration Programs Lung Cancers
Slide 21: Systemic Administration Demonstrated Dose-dependent OS Benefit
Systemic Administration Demonstrated Dose-dependent OS Benefit Key Clinical Takeaways Dose Escalation Single-arm Phase 1b Monotherapy Study in Solid Tumors Progressed from Last Prior Therapy Demonstrated feasibility and clinical benefit of multiple IV cycles A’ B’ • Median 5 prior lines of therapy G
Slide 22: Systemic Administration + Chemo Generated Encouraging Data: Expanded Access Program
Systemic Administration + Chemo Generated Encouraging Data : Expanded Access Program Key Clinical Takeaways Platinum refractory metastatic High-grade pancreatic cancer with cervical cancer with lung mets lung & liver mets Anti-tumor effect of IV Case Report (Pt #21A-06) Case Report (Pt.#21A-04) ❖ Re
Slide 23: Systemic Administration Program
Systemic Administration Program Key Takeaways Lung Cancer Clinical Trial Designs Ongoing Clinical Trials • All patients in these ongoing clinical trials are treated systemically and previously failed platinum-based therapy Clinical Patients Lung Cancer Clinical Trial Initial Interim Data Sponsor Tri
Slide 24: Phase 1b/2 Trial in Recurrent Small Cell Lung Cancer
Phase 1b/2 Trial in Recurrent Small Cell Lung Cancer Heavily Pretreated Patients with Platinum-Relapse or Platinum-Refractory Small Cell Lung Cancer Phase 1b, multi-center, dose escalation, open-label Phase 1b Endpoints N = up to 36 Primary Endpoint Key Inclusion Criteria - Safety and tolerability S
Slide 25: Phase 1b/2 SCLC Systemic Administration - Interim Data Readout
Phase 1b/2 SCLC Systemic Administration - Interim Data Readout As of data review cutoff date of December 23, 2025 Key Takeaways Data is suggestive of potential dose-response trend • 66% (2/3) achieved partial responses (PR) in highest dose cohort tested as of data review cutoff date (tumor reduction
Slide 26: Phase 2 Trial in Recurrent Non-small Cell Lung Cancer
Phase 2 Trial in Recurrent Non-small Cell Lung Cancer Patients with Non-small Cell Lung Cancer after First Progression while on Front-Line Immune Checkpoint Inhibitor-based Maintenance Multi-center, dose escalation, open-label n= up to 30 Three Dose Escalation Cohorts Key Inclusion Criteria Olvi-Vec
Slide 27: Phase 2 NSCLC Systemic Administration - Interim Data Readout
Phase 2 NSCLC Systemic Administration - Interim Data Readout As of data review cutoff date of December 31, 2025 Observed signals of anti-tumor activity and treatment tolerability Key Takeaways • Dose escalation cohorts achieved a 60% (3/5) disease control rate (3 stable disease (SD)) ➢ 2 stable dise
Slide 28: Industry Collaboration with Newsoara HYK Biopharmaceuticals Co., Ltd.
Industry Collaboration with Newsoara HYK Biopharmaceuticals Co., Ltd. HIGHLIGHTS 15 7 14 Compounds Clinical Stage IND Approvals 7/8 8 6/8 Small Molecules/ Completed/Ongoing Biologics Pre-clinical Studies Benny Li, PhD 4 2023 Top 10 Newsoara Founder and CEO 20+ yrs. global and China local pharma Plat
Slide 29: Intellectual Property: Market Exclusivity & Freedom to Operate
Intellectual Property: Market Exclusivity & Freedom to Operate Patent Portfolio: 21 issued patents and 7 pending applications; patent term expected to extend into 2038 Strong IP & Olvi-Vec: No third-party royalties due Regulatory Designations Long Duration of Regulatory / Marketing Exclusivity 29
Slide 30: Integrated Capabilities For Phase 3 And Launch
Integrated Capabilities For Phase 3 And Launch Key Takeaways Facilities and Operations based in Southern California GMP Manufacturing Headquarters • Large-scale manufacturing Westlake Village, CA, USA process (~4,050 SF) • Capacity for clinical studies and commercial launch needs Translational Resea
Slide 31: Accomplished Leadership Team
Accomplished Leadership Team Executive Team Board of Directors THOMAS ZINDRICK, JD Chairman of the Board JAMES L. TYREE, MBA Lead Independent Director Thomas Zindrick, JD Matthew Pulisic, MBA Jason Litten, MD Eric Groen, JD Chief Executive Officer Chief Financial Officer Chief Medical Officer Genera
Slide 32: Genelux Has Executed on Multiple Milestones and is Positioned for the Future
Genelux Has Executed on Multiple Milestones and is Positioned for the Future Regular Cadence of Important Program Milestones - Upcoming Trial Readouts have Potential to Redefine: ➢ Therapy (platinum sensitization in multiple indications) ➢ Modality (systemic administration of an oncolytic virus) Exe
Slide 33: Appendix
Redefining Immuno-Oncology Corporate Presentation | August 2026 Appendix
Slide 34: Olvi-Vec Seeks to Unleash Immune System Against Cancer
Olvi-Vec Seeks to Unleash Immune System Against Cancer Key Takeaways Innate Adaptive Olvi-Vec1 Immune Activation Immune Activation viral infection Olvi-Vec is being developed as a robust immune modulator that Oncolysis and • Increase Type I IFNs • APCs present (neo)antigens • Increase DAMPs / PAMPs
Slide 35: Olvi-Vec-Primed Immunochemotherapy: Reversing Platinum Resistance
Olvi-Vec-Primed Immunochemotherapy: Reversing Platinum Resistance Olvi-Vec-Induced Hot Tumor Pro-therapeutic gene expression Chemotherapy synergy [VIRO-15 Monotherapy Data] ___________________ ➢ Positive regulation of T-cell activating ➢ Immunogenic cell death and presentation of oncogenic neoantige
Slide 36: Accomplished Clinical Advisory Board
Accomplished Clinical Advisory Board Medical Director, Gynecologic Oncology, Robert Holloway, MD Dr. Holloway is the principal investigator for VIRO-15 and has served on several committees of the Society AdventHealth Cancer Institute CHAIRMAN of Gynecologic Oncology (SGO), including its Board of Dir
Slide 37: Olvi-Vec-Primed Immunochemotherapy Anti-tumor Activity: CA-125 Biomarker
Olvi-Vec-Primed Immunochemotherapy Anti-tumor Activity: CA-125 Biomarker Rapid, Common and Durable Responses CA-125 Decrease ORR by CA-125 o All PRROC Patients: 96% (25/26) o All PRROC Patients: 85% (22/26) o Platinum refractory patients: 85% (11/13) o Platinum refractory patients: 85% (11/13) 100 8
Slide 38: Olvi-Vec-Primed Immunochemotherapy Overcomes “Refractoriness”
Olvi-Vec-Primed Immunochemotherapy Overcomes “Refractoriness” Exemplary platinum-refractory patients, after platinum re-challenge, achieved PFS exceeding any prior lines 15B-15: • Stage IIIB high- grade serous • ECOG: 0 • BRCA negative • PD-L1 negative Overall Survival: 12.3 Months Failed 6 Prior Li
Slide 39: Olvi-Vec Demonstrated Oncolysis and Immune Activation
Olvi-Vec Demonstrated Oncolysis and Immune Activation Data from Phase 1b Monotherapy portion of VIRO-15 trial Key Takeaways Olvi-Vec Treatment on (Pt.#15A-01) (Pt.#15A-11) Days 3 & 4 Elimination of Cancer Cells after Increased Lymphocyte Infiltration in different cavities Olvi-Vec monotherapy shows
Slide 40: CD8+ T-cells: Infiltrating Lymphocytes are Prognostic for Response/Survival
CD8+ T-cells: Infiltrating Lymphocytes are Prognostic for Response/Survival Data from Phase 1b Monotherapy portion of VIRO-15 trial Pt# 15A-16 Pt# 15A-18 Pt# 15A-23 Pre-Olvi-Vec Olvi-Vec Induced Infiltration of CD8+ cells into CD4+ CD8+ CD4+ CD8+ CD4+ CD8+ Tumors Post-Olvi-Vec (prior to subsequent c
Slide 41: Long-lasting, Tumor-specific T cell Response Corresponds to Tumor Reduction
Long-lasting, Tumor-specific T cell Response Corresponds to Tumor Reduction Data from Phase 1b Monotherapy portion of VIRO-15 trial Confirms tumor-antigen presentation & immune activation/memory Case Report (Pt #15A-05) Key Takeaways Heavily pre-treated: 9 prior regimens of chemo+Avastin; no pre-exi
Slide 42: Olvi-Vec Demonstrated Anti-Tumor Response & Disease Control Observed
Olvi-Vec Demonstrated Anti-Tumor Response & Disease Control Observed Data from Phase 1b Monotherapy portion of VIRO-15 trial 42
Slide 43: Choice Platform Library: 500+ Vectors with 110+ Transgenes
Choice Platform Library: 500+ Vectors with 110+ Transgenes ✓ In vitro & in vivo tested: GLP Tox ready Engineered and selected clonal isolated (non-GMO) viral strains identified from Immune Modularity Molecules o IL-6/sIL-6R in vitro and in vivo selection criteria o IL-24 Cell Growth & Differentiatio
Slide 44: Olvi-Vec & Cisplatin Demonstrate Activity in Animal Models with Platinum-resistant Cancer Lines
Olvi-Vec & Cisplatin Demonstrate Activity in Animal Models with Platinum-resistant Cancer Lines Synergistic and Durable Antitumor Activity Ovarian Cancer Melanoma (OVCAR-3 cell line) (WM266.4 cell line) Untreated control cisplatin 3500 1h 68 2.0x 10^6 pfu/ 100µl t.v. 3000 1h 68 2.0x 10^6 pfu/ 100µl
Slide 45: Olvi-Vec & anti-PD-1: Enhanced Activity in Immune-competent Animal Model
Olvi-Vec & anti-PD-1: Enhanced Activity in Immune-competent Animal Model Pre-clinical Support for Treatment-naïve Resectable Non-small Cell Lung Cancer ➢Prolonged survival and enhanced anti-tumor activity from combination of oncolytic vaccinia virus Olvi-Vec (VV-ILP) and immune checkpoint inhibitor
Slide 46: Olvi-Vec: Ideal Backbone for Combination Therapy
Olvi-Vec: Ideal Backbone for Combination Therapy Converts Tumor Microenvironment to Inflammatory “Hot Spot” NCT01443260/TUE Study Induction of acute inflammatory cytokines (Th1-type related) VIRO-15 Study Massive inflammatory Baseline response after (C1D24) single dose of virus Up Regulates Immunomo